🔎 Trials Near Me

Home › Acute Biphenotypic Leukemia › Washington › Seattle

Acute Biphenotypic Leukemia clinical trials in Seattle, WA

15 studies for Acute Biphenotypic Leukemia are looking for participants at sites in and around Seattle (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

RecruitingPhase 1
  • Fred Hutchinson Cancer Center, Seattle
Ages 12 to 78 · All sexes · Updated Sep 29, 2026 · NCT03802695

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

RecruitingPhase 1
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT04375631

Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms

Recruiting
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07094750

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

RecruitingPhase 3
  • Seattle Children's Hospital, Seattle
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

RecruitingPhase 2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
6 Months – 65 Years · All sexes · Updated Jul 22, 2026 · NCT06013423

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

RecruitingPhase 1/2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Ages 18 to 75 · All sexes · Updated Jun 22, 2026 · NCT03128034

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

RecruitingPhase 1/2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Ages 18 to 75 · All sexes · Updated Jun 22, 2026 · NCT03670966

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

RecruitingPhase 2Healthy volunteers welcome
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
6 Months · All sexes · Updated May 29, 2026 · NCT04195633

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

RecruitingPhase 1
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Up to age 80 · All sexes · Updated May 18, 2026 · NCT03326921

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

RecruitingPhase 1/2Healthy volunteers welcome
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Ages 18 and older · All sexes · Updated May 15, 2026 · NCT06928662

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

RecruitingPhase 1/2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Ages 18 and older · All sexes · Updated Apr 17, 2026 · NCT04797767

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

RecruitingPhase 1
  • Seattle Children's Hospital, Seattle
Ages 1 to 21 · All sexes · Updated Dec 6, 2024 · NCT05476770

Acute Biphenotypic Leukemia trials in other cities

Other studies in Seattle

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.